4,746 Shares in Eli Lilly and Company (NYSE:LLY) Acquired by Texas Bank & Trust Co

Texas Bank & Trust Co purchased a new position in Eli Lilly and Company (NYSE:LLY) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 4,746 shares of the company’s stock, valued at approximately $3,664,000. Eli Lilly and Company comprises about 1.5% of Texas Bank & Trust Co’s portfolio, making the stock its 13th biggest position.

Other institutional investors also recently added to or reduced their stakes in the company. True Wealth Design LLC lifted its position in shares of Eli Lilly and Company by 12.9% during the 4th quarter. True Wealth Design LLC now owns 131 shares of the company’s stock worth $101,000 after buying an additional 15 shares during the last quarter. State of Wyoming lifted its position in shares of Eli Lilly and Company by 92.8% during the 4th quarter. State of Wyoming now owns 1,552 shares of the company’s stock worth $1,198,000 after buying an additional 747 shares during the last quarter. Stonebrook Private Inc. lifted its position in shares of Eli Lilly and Company by 2.0% during the 4th quarter. Stonebrook Private Inc. now owns 2,864 shares of the company’s stock worth $2,211,000 after buying an additional 56 shares during the last quarter. Strategic Wealth Partners Ltd. lifted its position in shares of Eli Lilly and Company by 19.8% during the 4th quarter. Strategic Wealth Partners Ltd. now owns 14,301 shares of the company’s stock worth $11,040,000 after buying an additional 2,359 shares during the last quarter. Finally, Strive Asset Management LLC purchased a new stake in shares of Eli Lilly and Company during the 4th quarter worth approximately $462,000. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Stock Performance

Shares of LLY opened at $757.23 on Friday. The company has a debt-to-equity ratio of 2.00, a quick ratio of 0.97 and a current ratio of 1.15. The stock has a market capitalization of $717.65 billion, a P/E ratio of 64.67, a P/E/G ratio of 1.40 and a beta of 0.48. The company’s fifty day moving average is $797.84 and its two-hundred day moving average is $805.85. Eli Lilly and Company has a 1 year low of $677.09 and a 1 year high of $972.53.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Thursday, May 1st. The company reported $3.34 earnings per share (EPS) for the quarter, missing the consensus estimate of $4.64 by ($1.30). The firm had revenue of $12.73 billion during the quarter, compared to analyst estimates of $12.77 billion. Eli Lilly and Company had a net margin of 23.51% and a return on equity of 85.24%. The business’s quarterly revenue was up 45.2% compared to the same quarter last year. During the same period in the prior year, the firm posted $2.58 earnings per share. On average, sell-side analysts predict that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 10th. Stockholders of record on Friday, May 16th will be paid a dividend of $1.50 per share. The ex-dividend date of this dividend is Friday, May 16th. This represents a $6.00 dividend on an annualized basis and a dividend yield of 0.79%. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 48.82%.

Insider Transactions at Eli Lilly and Company

In other news, CAO Donald A. Zakrowski sold 1,000 shares of the company’s stock in a transaction on Thursday, March 13th. The shares were sold at an average price of $818.24, for a total transaction of $818,240.00. Following the transaction, the chief accounting officer now directly owns 5,840 shares of the company’s stock, valued at $4,778,521.60. This represents a 14.62% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Corporate insiders own 0.13% of the company’s stock.

Analysts Set New Price Targets

Several analysts have recently weighed in on LLY shares. Cantor Fitzgerald started coverage on shares of Eli Lilly and Company in a research report on Tuesday, April 22nd. They set an “overweight” rating and a $975.00 price objective for the company. Hsbc Global Res cut shares of Eli Lilly and Company from a “strong-buy” rating to a “moderate sell” rating in a report on Monday, April 28th. UBS Group cut their target price on shares of Eli Lilly and Company from $1,100.00 to $1,050.00 and set a “buy” rating on the stock in a report on Friday, May 2nd. StockNews.com raised shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a report on Friday, February 7th. Finally, Morgan Stanley reaffirmed an “overweight” rating on shares of Eli Lilly and Company in a report on Thursday, May 1st. One research analyst has rated the stock with a sell rating, two have issued a hold rating and eighteen have issued a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $1,011.37.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.